Member Info for AndytheMKDon

Some people are probably doubting todays RNS to see if the €2M sales order and contract are in place by the end of the month as the CEO has stated. However the RNS will have been checked and authorised by the Nomad, if it doesn't materialise then the CEO's and the Nomads reputations are in tatters. If as he states it's a done deal and the news comes within the next few weeks then I can't see an entry point below where it is now if that is what some are waiting for.. Last weeks bargain bucket prices are gone me thinks and it was only forced down that low to let all the spread-bet shorts to be closed out..

Be patient, today EQT announced equipment orders worth circa €4M and that they had taken a 20% share in a 20M project off the back of supplying €2M of this equipment as their skin in the game. The CEO has just tweeted that this is just one of five projects soon to be announced. If they are of a similar magnitude then an order book in the range of €20M, or putting it simply, double the companies current market cap looks likely and future revenue streams guaranteed.

Bought these a couple of weeks ago for a quick turn and 20% profit, change of mind and just added another 1m shares to holding.. :+)

Hard to believe that with such a strong relationship and order book being built with Phoenix that they won't take some sort of ownership in EQT or at least insist upon a non-exec director of their choice being added to the board of EQT directors.

I have to agree with you to some extent regarding Sierra, however I think the law of the jungle will ultimately apply. We were to small to take Chk1 forwards hence SRRA took us through P1-P2 and now they are to small to take it through P3 and to market hence my belief they will get swallowed up, and soon, especially if their share price keeps sliding..

Something has to give soon with Sierra they were down 23% yesterday, they can't keep sitting on the fence regarding funding.. I think they'll get taken out, the were >$3..00 per share a little while ago and are now circa 90 cents.. Cue Lilly from stage left..

MM's are fiddling around to try and scare a few sellers who might have been underwater and also profit takers bailing from their recent low entry points.. Once there is no stock supply and demand will take over..

Look at the balance sheet, no revenue generated for the last five years!! Today they announce a 20% stake in a €20M project from sales of equipment already delivered to the tune of €2M, and a further order of €2.2M by month end for additional equipment and expertise plus down payments. To be followed by 20% of $4M per annum revenue on commissioning and further milestone payments.. The penny will drop soon I'm sure..

Once people understand that the RNS today has seen EQT generate their first income from sales and a pretty substantial income and payments to come off the back of this contract then the price will reflect true value. EQT only has a mcap of 10M€ hence the order announced today represents around half of their mcap with milestones and future revenue stream to come. Click on the fundamentals tab above and you will see the significance of todays announcement.

They should have dealt with their funding gap before now.. They have two strong products they wish to get licensed and $90m just won't cut the mustard.. SRRA could be taken out on the cheap by one of the major's which would be great news for SAR.. ;+)

The take from the Sierra presentation is 737 is not their priority, momelotinib is, hence despite the great progress they will look for options how to progress 737, it's in their statement below. Therefore my conclusion is 737 is up for sale given Sierra's current huge push to put it in the shop window. They know to progress it any further will result in more spend and milestone payments, both of which they will be keen to avoid, also Sierra's management style in the past has been to develop products to a point and then sell them. Watch this space.

https://www.investegate.co.uk/sareum-holdings-plc--sar-/rns/key-takeaways-from-sra737-webcast-at-asco/201906031600029855A/

"These positive data indicate that SRA737 is a demonstrably active anti-cancer drug that we believe warrants further development. The initial efficacy and favorable tolerability profile described at ASCO also enables several potentially promising opportunities for its development in combination with other therapeutics, in particular with PARP inhibitors and immunotherapy agents where we have previously reported robust preclinical efficacy data," said Dr. Nick Glover, President and CEO of Sierra Oncology. "We also look forward to announcing regulatory clarity for our lead asset momelotinib in the near-term. We have been holding productive discussions with regulators and continue to prepare for a Phase 3 clinical trial intended to potentially support its registration. Given momelotinib is our lead drug candidate and highest priority, we will be exploring options to enable the continued advancement of SRA737 in the context of our emerging pipeline."

I'm guessing the market can see SRRA doesn't have the wedge to follow through the trials on 737 to a conclusion especially as they want to progress momelotinib. Lilly will be aware that an effective Chk1 inhibitor with good results and no toxicity problems is available at a knock down price. Seems a bit to much of a coincidence that Lilly stopped their trials just weeks before 737 data published. Something has to give soon to break the current impasse upon how 737 progresses, either SRRA do a raise to fund further trials or 737 gets bought, I'll plump for the later which would explain SRRA's current marketing drive..

Down 16%.. I guess that's due to their cash position..

Yep.. slide shows ready for P3 trials.. ;+)

We should get details of how they intend to proceed which should give us a clue as to timelines on milestone payments. Given they are also presenting at other events this week we could well get a statement upon if they are going to fund the project going forwards of farm-out. Nice to see some progress on sp lets hope this is the start of a re-rate. gla. Andy.

Mid may 2018 the share price was 0.33p and by mid June 2018 was 1.2p i.e. a four bagger.. I think I'll ignore the "doom prophets" here and wait for this to bag up on next news.. :+)

Shorts being closed and switched to long positions ready for the rampathon.. :+)

Couldn't make it up..löl

Time to close the short fella.. ;+)